Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Homoharringtonine: history, current research, and future direction.

H M Kantarjian1, M Talpaz, V Santini

  • 1Department of Leukemia, M. D. Anderson Cancer Center, Houston, Texas 77030, USA. hkantarj@mdanderson.org

Cancer
|December 18, 2001
PubMed
Summary

Homoharringtonine (HHT) shows promise in treating hematologic malignancies, particularly leukemia. Further research is needed to optimize its use and explore new derivatives for improved efficacy and reduced toxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Moving toward individualized target-based therapies in acute myeloid leukemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Translation and cross-cultural adaptation into Italian of the self-administered FLARE-RA questionnaire for rheumatoid arthritis.

Reumatismo·2020
Same author

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Leukemia·2020
Same author

Health-related quality of life burden in scleroderma patients treated with two different intravenous iloprost regimens.

Reumatismo·2019
Same author

Therapeutic targeting of membrane-associated GRP78 in leukemia and lymphoma: preclinical efficacy in vitro and formal toxicity study of BMTP-78 in rodents and primates.

The pharmacogenomics journal·2017
Same author

Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia.

Blood cancer journal·2017

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Cephalotoxine esters, including homoharringtonine (HHT), have demonstrated preliminary efficacy in leukemia treatment.
  • Initial studies in China and the U.S. indicated encouraging activity of HHT in hematologic cancers.

Purpose of the Study:

  • To review existing literature on homoharringtonine (HHT).
  • To examine preclinical studies and Phase I-II trials of HHT in hematologic malignancies and solid tumors.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of Phase I-II trials investigating HHT in various cancers.

Main Results:

  • HHT and analogues induce cancer cell differentiation and apoptosis.

Related Experiment Videos

  • Positive results observed in acute myeloid leukemia, myelodysplastic syndrome, acute promyelocytic leukemia, and chronic myeloid leukemia (CML).
  • Negative results in solid tumors; cardiovascular complications noted with short infusions, reduced with continuous schedules.

    • Conclusions:

    • Homoharringtonine (HHT) and its derivatives exhibit promising activity in hematologic malignancies.
    • Further investigation is warranted to optimize HHT therapy and develop novel derivatives.